Newronika raised €13.6M in a Series B funding round led by Fondazione ENEA Tech e Biomedical to expand clinical validation and commercialization of its adaptive DBS system.
Newronika has successfully completed a €13.6M Series B funding round, led by new investor Fondazione ENEA Tech e Biomedical, with participation from existing investors. The funds will enable the company to expand its clinical validation and commercialization efforts for its innovative adaptive DBS system for Parkinson's patients.
Who to call at Newronika, and when
A new round usually means Newronika is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Newronika raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Newronika, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Newronika. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Newronika
Location
Milan, Lombardy, Italy
About
Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Newronika raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MilanBiotechnologyHealth CareArtificial IntelligenceTherapeuticsMachine Learning